Volume 99, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa. Immunization with five doses at 0, 4, 8, 12, and 20 weeks of 2.7 × 10 PfSPZ of PfSPZ Vaccine gave 65% vaccine efficacy (VE) at 24 weeks against mosquito bite CHMI in U.S. adults and 52% (time to event) or 29% (proportional) VE over 24 weeks against naturally transmitted Pf in Malian adults. We assessed the identical regimen in Tanzanians for VE against PfSPZ Challenge. Twenty- to thirty-year-old men were randomized to receive five doses normal saline or PfSPZ Vaccine in a double-blind trial. Vaccine efficacy was assessed 3 and 24 weeks later. Adverse events were similar in vaccinees and controls. Antibody responses to Pf circumsporozoite protein were significantly lower than in malaria-naïve Americans, but significantly higher than in Malians. All 18 controls developed Pf parasitemia after CHMI. Four of 20 (20%) vaccinees remained uninfected after 3 week CHMI ( = 0.015 by time to event, = 0.543 by proportional analysis) and all four (100%) were uninfected after repeat 24 week CHMI ( = 0.005 by proportional, = 0.004 by time to event analysis). SPZ Vaccine was safe, well tolerated, and induced durable VE in four subjects. Controlled human malaria infection by DVI of PfSPZ Challenge appeared more stringent over 24 weeks than mosquito bite CHMI in United States or natural exposure in Malian adults, thereby providing a rigorous test of VE in Africa.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. WHO, 2017. World Malaria Report 2017. Geneva, Switzerland: World Health Organization.
  2. GBD 2015 Mortality and Causes of Death Collaborators, 2016. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 14591544.
  3. Gething PW, 2016. Mapping Plasmodium falciparum mortality in Africa between 1990 and 2015. N Engl J Med 375: 24352445.
  4. Richie TL, 2015. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33: 74527461.
  5. Clyde DF, Most H, McCarthy VC, Vanderberg JP, , 1973. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 266: 169177.
  6. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW, , 1974. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 68: 258259.
  7. Hoffman SL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 11551164.
  8. Hoffman SL, 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97106.
  9. Epstein JE, 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334: 475480.
  10. Seder RA, VRC 312 Study Team , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 13591365.
  11. Epstein JE, 2017. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2: e89154.
  12. Ishizuka AS, 2016. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22: 614623.
  13. Lyke KE, 2017. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 27112716.
  14. Sissoko MS, 2017. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498509.
  15. Roestenberg M, 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 513.
  16. Sheehy SH, 2013. Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One 8: e65960.
  17. Hodgson SH, 2014. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 5: 686.
  18. Mordmüller B, 2015. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 14: 117.
  19. Shekalaghe S, 2014. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 91: 471480.
  20. Gomez-Perez GP, 2015. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14: 306.
  21. Lell B, 2018. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg 98: 508515.
  22. Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF, , 2013. Multiplex qPCR for detection and absolute quantification of malaria. PLoS One 8: e71539.
  23. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I, , 2015. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med 12: e1001788.
  24. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP, , 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119: 113125.
  25. Mordmuller B, 2017. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542: 445449.
  26. Lamoreaux L, Roederer M, Koup R, , 2006. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 1: 15071516.
  27. Haddy TB, Rana SR, Castro O, , 1999. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133: 1522.
  28. Hammerschmidt DE, , 1999. It’s as simple as black and white! Race and ethnicity as categorical variables. J Lab Clin Med 133: 1012.
  29. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig RS, Nussenzweig V, , 1987. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664666.
  30. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF, , 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573576.
  31. Weiss WR, Jiang CG, , 2012. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One 7: e31247.
  32. Schoenbrunn A, 2012. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. J Immunol 189: 59855994.
  33. Fernandez-Ruiz D, 2016. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infection. Immunity 45: 889902.
  34. Muyanja E, 2014. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 124: 31473158.
  35. Hartgers FC, Yazdanbakhsh M, , 2006. Co-infection of helminths and malaria: modulation of the immune responses to malaria. Parasite Immunol 28: 497506.
  36. Purkins L, Love ER, Eve MD, Wooldridge CL, Cowan C, Smart TS, Johnson PJ, Rapeport WG, , 2004. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a phase I unit. Br J Clin Pharmacol 57: 199208.

Data & Media loading...

Supplementary Data

Supplemental Tables

  • Received : 27 Dec 2017
  • Accepted : 19 Apr 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error